Molecular Insight Pharmaceuticals Presents Oncology Data at Society of Nuclear Medicine 2010 Annual Meeting
08 Giugno 2010 - 10:30PM
Marketwired
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), announced
the presentation of nonclinical data demonstrating the utility of
the Company's novel radiopharmaceutical compounds for the molecular
imaging of prostate and other tumors at the Society of Nuclear
Medicine (SNM) annual meeting. Data from four products were
presented in five oral sessions and one poster presentation at the
meeting, taking place June 5-9, 2010, in Salt Lake City. In
addition, Molecular Insight announced the receipt of SNM's 2010
Berson-Yalow Award for a nonclinical study demonstrating the
potential of Molecular Insight's compound 99mTc-MIP-1340 to provide
accurate imaging of metastatic prostate cancer. The Berson-Yalow
Award honors originality and research that makes the most
significant contributions to basic or clinical radioassay science.
"We are proud that our peers continue to single out our research
as of the highest caliber in our field. This is Molecular Insight's
second Berson-Yalow award in four years and validates the way we
approach our work and our science," said John W. Babich, Ph.D.,
Executive Vice President, Chief Scientific Officer, President of
Research and Development. "Molecular Insight has established a deep
pipeline of novel radio-imaging and radiotherapeutic compounds
capable of binding to specific disease-related changes at the
cellular level for a given cancer for highly targeted results."
Molecular Insight's Award-Winning Research on
Prostate Cancer Imaging 99mTc-MIP-1340 is a small molecule
imaging pharmaceutical that binds to prostate specific membrane
antigen (PSMA), a protein highly expressed by prostate tumor cells.
Current imaging techniques are unable to provide highly specific
imaging of metastatic prostate cancer. 99mTc-MIP-1340 is intended
to provide a sensitive and specific means of imaging tumor burden
throughout the body, in both soft tissue and bone. 99mTc-MIP-1340
was selected from a family of compounds enabled by Molecular
Insight's SAAC™ technology and is in nonclinical development for
the diagnosis and staging of prostate cancer.
As reported by lead author Shawn Hillier, Principal Scientist at
Molecular Insight Pharmaceuticals, in the award-winning abstract,
"99mTc-MIP-1340, a small molecule inhibitor of PSMA for molecular
imaging of prostate cancer" (Abstract #481), preclinical results
confirm that 99mTc-MIP-1340 binds specifically and with high
affinity to PSMA and accumulates in human prostate cancer
xenografts. The research team from Molecular Insight demonstrated
that the incorporation of the novel polar 99mTc-SAAC chelate
provides an attractive pharmacokinetic profile for imaging prostate
cancer metastases using single proton emission computed tomography
(SPECT).
Additional Presentations by Molecular Insight
at the SNM Annual Meeting Preclinical data were also presented
on Molecular Insight's recent evaluation of a 99mTc-SAAC octreotide
analog for targeting neuroendocrine cancer, and a series of
99mTc-labeled carbonic anhydrase inhibitors for assessing tumor
hypoxia, as well as on the utility of Trofex™, a 123I-labeled PSMA
inhibitor, for monitoring the success of chemotherapy in
preclinical prostate cancer models. Trofex is Molecular Insight's
lead clinical molecular imaging candidate for the diagnosis and
monitoring of metastatic prostate cancer. To access Molecular
Insight Pharmaceutical's SNM abstracts, please visit:
http://www.molecularinsight.com/MediaRoom/ScientificPresentations.aspx
http://www.molecularinsight.com/MediaRoom/ScientificPosters.aspx
- Researchers from Molecular Insight Pharmaceuticals examined the
biochemical and pharmacokinetic properties of several new
99mTc-labeled octreotide analogs incorporating novel polar single
amino acid chelators (SAAC) for molecular targeting of
neuroendocrine tumors. As reported by lead author John Marquis,
Senior Scientist at Molecular Insight Pharmaceuticals, in a
presentation titled "Evaluation of 99mTc-MIP-1407, an octreotide
analog for targeting neuroendocrine tumors" (Abstract # 482),
99mTc-MIP-1407 binds specifically and with high affinity to
somatostatin receptor positive tumors. The novel polar SAAC
chelator affords a pharmacokinetic profile that makes
99mTc-MIP-1407 attractive for clinical evaluation in patients with
neuroendocrine tumors.
- In a scientific poster presentation titled "99mTc-labeled
carbonic anhydrase IX (CA IX) inhibitors for molecular imaging of
cancer" (Abstract # 1533), the Molecular Insight research team
concluded that novel 99mTc-labeled compounds incorporating polar
SAAC derived chelators bind to CA IX with high affinity and
selectivity, and accumulate in HeLa tumor xenografts. CA IX is
upregulated in cancer in response to hypoxia making it an
attractive molecular target for radiopharmaceutical development by
Molecular Insight. These compounds may be exploited to
significantly impact the current paradigm for diagnosis, staging,
treatment selection and therapy of solid tumors.
- In an oral presentation titled "Influence of functionalized
chelators on affinity and pharmacokinetics of 99mTc(CO)3-labeled
small molecules targeting prostate specific membrane antigen
(PSMA)" (Abstract # 250), lead author Kevin Maresca, Associate
Director of Chemistry at Molecular Insight, reported on the
discovery of 99mTc-labeled PSMA-targeting radiopharmaceuticals. The
data suggest that ligands containing novel SAAC derived polar
substituents exhibited high affinity, substantial prostate cancer
uptake, and diminished hepatobiliary accumulation. These novel
chelators have led to the identification of 99mTc-labeled
radiopharmaceuticals with ideal properties for imaging prostate
cancer.
- Paclitaxel is used in the treatment of advanced and recurrent
prostate cancer. Since traditional imaging endpoints in oncology
trials are not applicable for metastatic prostate cancer, better
ways of following response to treatment are needed. In an oral
presentation, Molecular Insight reported that 123I-MIP-1072,
Trofex™, which targets prostate specific membrane antigen (PSMA),
detected growth inhibition of prostate cancer following paclitaxel
therapy. As a result, 123I-MIP-1072 may allow monitoring of
prostate cancer progression in patients before, during, and after
chemotherapy. These nonclinical data were presented by lead author,
Dr. Shawn Hillier, in a talk titled "Molecular imaging for
monitoring prostate cancer response to paclitaxel" (Abstract #
14).
About Molecular Insight's SAAC Technology
Single Amino Acid Chelate, or SAAC, is Molecular Insight's unique
metal binding chemistry platform technology. It represents a new
family of compounds with superior metal binding properties for
leading radionuclides used for molecular imaging and radiotherapy,
namely technetium-99m, rhenium-186 and rhenium-188. This technology
incorporates a metal binding, or chelating, group that can rapidly
and efficiently bind to technetium or rhenium for diagnostic and
therapeutic applications, and an amino acid portion that allows it
to be incorporated into any peptide sequence through the use of
conventional peptide chemistry.
About Molecular Insight Pharmaceuticals,
Inc. Molecular Insight Pharmaceuticals is a clinical-stage
biopharmaceutical company and pioneer in molecular medicine. The
Company is focused on the discovery and development of targeted
therapeutic and imaging radiopharmaceuticals for use in oncology.
Molecular Insight has five clinical-stage candidates in
development. For further information on Molecular Insight
Pharmaceuticals, please visit www.molecularinsight.com.
Forward Looking Statements Statements in
this release that are not strictly historical in nature constitute
"forward-looking statements." Such statements include, but are not
limited to, statements about the capability of the Company's
several novel radiopharmaceutical compounds for the molecular
imaging of prostate and other tumors; the potential of Molecular
Insight's compound 99mTc-MIP-1340 to provide accurate imaging of
metastatic prostate cancer; the potential impact of several
compounds on the current paradigm for diagnosis, staging, treatment
selection and therapy of solid tumors; and the capability of
Trofex™ for monitoring of prostate cancer progression in patients
before, during, and after chemotherapy. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other factors that may cause the actual results of Molecular
Insight to be materially different from historical results or from
any results expressed or implied by such forward-looking
statements. These factors include, but are not limited to, risks
and uncertainties related to the progress, timing, cost, and
results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for product
candidates; competition from other pharmaceutical or biotechnology
companies; and the additional risks discussed in filings with the
Securities and Exchange Commission (SEC). The Company's SEC filings
are available through the SEC's Electronic Data Gathering Analysis
and Retrieval system (EDGAR) at http://www.sec.gov. Press releases
for Molecular Insight Pharmaceuticals, Inc. are available on our
website: http://www.molecularinsight.com. If you would like to
receive press releases via e-mail, please contact:
investor@molecularinsight.com. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Molecular Insight undertakes no obligation to revise or update this
release to reflect events or circumstances after the date
hereof.
Contact: Investors Chuck Abdalian Chief Financial
Officer (617) 871-6618 cabdalian@molecularinsight.com Media
Martin A. Reynolds Manager Corporate Communications (617) 871-6734
mreynolds@molecularinsight.com Susan Pietropaolo BCC Partners (201)
923-2049 spietropaolo@bccpartners.com
Grafico Azioni Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Storico
Da Set 2023 a Set 2024